Company Overview - NLS Pharmaceutics Ltd. is a global development-stage biopharmaceutical company focused on innovative therapies for rare and complex central nervous system disorders [3] - Kadimastem is a clinical stage cell therapy company developing proprietary cell products for various medical conditions, including ALS and diabetes [4][5] Merger Details - NLS is planning a shareholder meeting for final approval of the merger with Kadimastem, highlighting their commitment to addressing unmet medical needs in the biopharmaceutical sector [1] - Kadimastem's shareholders have approved the merger, indicating confidence in the anticipated value creation from the combined strengths of both companies in biotechnology [2] - Both companies aim to align their efforts to become a leading force in developing therapies for critical health challenges as the merger process progresses [2] Leadership Statements - Ronen Twito, CEO of Kadimastem, expressed optimism about the merger, emphasizing the expected value creation and growth opportunities [2] - Alex Zwyer, CEO of NLS, noted the significance of receiving approval from Kadimastem's shareholders and the commitment to collaborative efforts in biotechnology [2]
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics